Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial …
S Glatt, D Baeten, T Baker, M Griffiths… - Annals of the …, 2018 - ard.bmj.com
Objective Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-
mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and …
mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and …
First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
S Glatt, E Helmer, B Haier… - British journal of …, 2017 - Wiley Online Library
Aims To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high
burden for patients and limited existing therapeutic options. Objective To evaluate the …
burden for patients and limited existing therapeutic options. Objective To evaluate the …
[HTML][HTML] Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F
R Adams, A Maroof, T Baker, ADG Lawson… - Frontiers in …, 2020 - frontiersin.org
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17
therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F …
therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F …
[HTML][HTML] Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury
M Pedroza, DJ Schneider, H Karmouty-Quintana… - PloS one, 2011 - journals.plos.org
Background Chronic lung diseases are the third leading cause of death in the United States
due in part to an incomplete understanding of pathways that govern the progressive tissue …
due in part to an incomplete understanding of pathways that govern the progressive tissue …
[HTML][HTML] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study
A Shock, L Burkly, I Wakefield, C Peters… - Arthritis research & …, 2015 - Springer
Abstract Introduction CD40 ligand (CD40L) blockade has demonstrated efficacy in
experimental autoimmune models. However, clinical trials of hu5c8, an anti-human CD40L …
experimental autoimmune models. However, clinical trials of hu5c8, an anti-human CD40L …
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma …
B Smith, A Kiessling, R Lledo-Garcia, KL Dixon… - MAbs, 2018 - Taylor & Francis
ABSTRACT Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal
Fc receptor (FcRn) monoclonal antibody (IgG4P), has been developed to reduce pathogenic …
Fc receptor (FcRn) monoclonal antibody (IgG4P), has been developed to reduce pathogenic …
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
S Shaw, T Bourne, C Meier, B Carrington, R Gelinas… - MAbs, 2014 - Taylor & Francis
Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely
implicated in autoimmune disease. Here, we describe the discovery and characterization of …
implicated in autoimmune disease. Here, we describe the discovery and characterization of …
[HTML][HTML] Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling
S Cole, J Murray, C Simpson, R Okoye… - Frontiers in …, 2020 - frontiersin.org
IL-23 is considered a critical regulator of IL-17 in Th17 cells; however, its requirement for
inducing IL-17 production in other human immune subsets remains incompletely …
inducing IL-17 production in other human immune subsets remains incompletely …
Bimekizumab for the treatment of psoriatic arthritis
Y Tanaka, S Shaw - Expert Review of Clinical Immunology, 2024 - Taylor & Francis
ABSTRACT Introduction Interleukin (IL)-17A and IL-17F have overlapping roles in pro-
inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease …
inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease …